Phoslyra

Hyperphosphataemia, Communicable Diseases, Dialysis therapy + 4 more
Treatment
3 FDA approvals
4 Active Studies for Phoslyra

What is Phoslyra

Calcium acetateThe Generic name of this drug
Treatment SummaryCalcium acetate is a compound made from calcium and acetic acid. It's also known as the acetate of lime. The anhydrous form of this compound is very absorbent, so it usually comes in the form of the monohydrate.
ProcalAmineis the brand name
Phoslyra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
ProcalAmine
Calcium acetate
1982
77

Approved as Treatment by the FDA

Calcium acetate, otherwise known as ProcalAmine, is approved by the FDA for 3 uses which include Kidney Failure, Chronic and End-stage Renal Failure (ESRF) .
Kidney Failure, Chronic
Helps manage End-stage Renal Failure (ESRF)
End-stage Renal Failure (ESRF)
Helps manage End-stage Renal Failure (ESRF)
Hyperphosphataemia
Helps manage Hyperphosphataemia

Effectiveness

How Phoslyra Affects PatientsPatients with serious kidney problems may build up phosphate in their bodies, which can lead to high blood levels of parathyroid hormone and calcium deposits in the body. To help control this, dietary phosphate needs to be reduced, as well as using a medication called calcium acetate to bind to any dietary phosphate and remove it from the body. This helps keep the level of phosphorus in the blood below 6.0 mg/dl. Calcium acetate dissolves easily and helps bind phosphate in the small intestine before it is absorbed.
How Phoslyra works in the bodyCalcium acetate and other calcium salts help manage phosphate levels in the body. They do this by binding to the phosphate found in food, preventing it from being absorbed into your bloodstream.

When to interrupt dosage

The prescribed dosage of Phoslyra is contingent upon the diagnosed condition, including Kidney, Hyperphosphataemia and Kidney Failure, Chronic. The amount of dosage is dependent on the mode of administration (e.g. Intravenous or Topical) specified in the table below.
Condition
Dosage
Administration
Hyperphosphataemia
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral
Kidney
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral
high phosphate levels
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral
Astringent
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral
Communicable Diseases
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral
Dialysis therapy
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral
Kidney Failure, Chronic
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Injection - Intravenous, Injection, Intravenous, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Liquid, Solution - Intravenous, Liquid - Intravenous, Tablet, coated, Tablet, coated - Oral

Warnings

Phoslyra Contraindications
Condition
Risk Level
Notes
Hypercalcemia
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Phoslyra.
Common Phoslyra Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Calcium acetate may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
Dobutamine
Minor
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium acetate.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Moderate
Calcium acetate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acebutolol
Moderate
The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium acetate.
Acetyldigitoxin
Moderate
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
Phoslyra Toxicity & Overdose RiskThe lowest toxic dose of oral rat is 4280mg/kg. Symptoms of overdose may include constipation, lack of appetite, nausea, vomiting, confusion, loss of consciousness, and difficulty speaking.

Phoslyra Novel Uses: Which Conditions Have a Clinical Trial Featuring Phoslyra?

There are currently 5 active studies evaluating the potential of Phoslyra to reduce Kidney-related high phosphate levels and Hyperphosphataemia.
Condition
Clinical Trials
Trial Phases
high phosphate levels
0 Actively Recruiting
Kidney Failure, Chronic
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Hyperphosphataemia
0 Actively Recruiting
Dialysis therapy
4 Actively Recruiting
Not Applicable, Phase 3, Phase 4
Astringent
0 Actively Recruiting
Kidney
0 Actively Recruiting

Patient Q&A Section about phoslyra

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Phoslyra used for?

"Phoslyra is a medication indicated for reducing the serum phosphorus levels in patients with end stage renal disease. It works by binding to phosphate in the gastrointestinal tract, thus preventing its absorption."

Answered by AI

What is calcium acetate used for?

"Calcium acetate is a medication used to treat hyperphosphatemia (too much phosphate in the blood) in patients with end stage kidney disease who are on dialysis. Calcium acetate works by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed."

Answered by AI

How do you take Phoslyra?

"You should take this medication with each meal, and the dosage will be based on your medical condition and how you respond to treatment. If you're using the liquid form, make sure to use a medication-measuring device or spoon to get the correct dose. Don't use a household spoon, because you might not get the right amount."

Answered by AI

Does calcium acetate come in liquid?

"Take calcium acetate with each meal, as directed by your doctor."

Answered by AI

Clinical Trials for Phoslyra

Image of London Health Sciences Centre in London, Canada.

Exercise for Dialysis

18 - 79
All Sexes
London, Canada
Patients receiving regular hemodialysis (HD) treatments are at a higher risk of cardiovascular events and death as HD can cause a decrease in the pumping of the heart during treatment called 'stunning'. Intradialytic exercise has emerged as a safe and effective non-drug approach to improve cardiovascular health and is now recommended for patients undergoing HD. It is currently advised that HD patients engage in at least 30 minutes of moderate to vigorous exercise three times per week. This study will evaluate the impact of exercise intensity in the HD population and determine if high impact exercise can offer better protection to the heart against HD-induced myocardial stunning.
Recruiting
Has No Placebo
London Health Sciences CentreChris McIntyre, MBBS DM
Image of Rocky Mountain Kidney Care - Lone Tree in Lone Tree, United States.

AP301 for High Phosphate Levels

Any Age
All Sexes
Lone Tree, CO
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.
Phase 3
Recruiting
Rocky Mountain Kidney Care - Lone Tree (+18 Sites)Alebund Pharmaceuticals
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security